Dentsply Sirona stock: UBS cuts target to $13, keeps Buy
Published on 11/17/2026 at 13:45 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSUBS lowers target after weak quarter
- UBS analyst Kevin Caliendo reduced the price target while maintaining a Buy rating.
- The bank said limited 2027 visibility could keep the shares range-bound near term.
- The lower target followed weaker third-quarter results and greater uncertainty around the company’s growth outlook.
UBS lowered its price target for Dentsply Sirona to 13 US dollars from 17 US dollars on Monday, November 16, while keeping a Buy rating on the shares. Markets Insider attributed the action to UBS analyst Kevin Caliendo.
Lower target reflects weaker visibility
Caliendo said Dentsply Sirona’s disappointing third-quarter results had increased uncertainty around its growth and earnings outlook. The analyst also expects the company’s turnaround to take time, while limited visibility for 2027 could keep the shares range-bound in the near term.
The target cut follows Dentsply Sirona’s third-quarter update, which showed weaker operating momentum and prompted management to reduce its full-year 2026 outlook. The company’s revised expectations are part of the backdrop to UBS’s more cautious valuation, even though the bank retained its Buy stance.
Current trading level
Dentsply Sirona stock traded at 8.13 euros on Lang & Schwarz at 13:36 CET on Tuesday, November 17, 2026. The quote was unchanged from the previous close shown for the same trading venue.
Dentsply Sirona
- Company: Dentsply Sirona Inc.
- ISIN: US24906P1093
- Ticker: XRAY
- Home exchange: Nasdaq
- Lang & Schwarz quote: 8.13 euros at 13:36 CET on November 17, 2026
- UBS price target: 13 US dollars, lowered from 17 US dollars on November 16, 2026
The Nasdaq Composite market environment provides the broader setting for US-listed medical-equipment shares.
